Solid Cancers: Clinical Trials

20 completed, 4 recruiting, 3 terminated, 2 not yet recruiting. 29 Phase 1, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	29	Completed 20, Recruiting 4, Terminated 3, Not yet recruiting 2
Phase 2	3	Recruiting 2, Not yet recruiting 1

Follow Solid Cancers: new trials by email Literature Review of Solid Cancers trials Research Report on Solid Cancers

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR JY016 - Solid Cancers	Phase 1 / Phase 2	Recruiting	Biotech Pharmaceutical Co., Ltd.	228	2026-05-20	2026-11-04
An Antibody-armored Dendritic Cell in Patients With Solid Tumors Armored Dendritic Cell Injection - Solid Cancers, Adjuvant Therapy	Phase 1	Recruiting	Shanghai Cell Therapy Group Co.,Ltd	8	2026-02-05	2026-03-18
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg - Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1 / Phase 2	Recruiting	Beijing Tide Pharmaceutical Co., Ltd	266	2025-12-03	2026-01-28
A Study to Evaluate the Safety and Tolerability of EP0089 EP0089-101 - Solid Cancers, Solid Tumours	Phase 1 / Phase 2	Not yet recruiting	Ellipses Pharma	190	2025-09-01	2025-06-22
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. LXP1788 is administered intravenously via Port-A - Solid Tumor Malignancies, Cancer, Solid Cancers	Phase 1	Recruiting	LaunXP Biomedical Co., Ltd.	24	2024-12-31	2025-03-19
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway DAT-2645 tablet - Solid Cancers, BRCA Mutation	Phase 1	Not yet recruiting	Danatlas Pharmaceuticals Co., Ltd	112	2024-11-01	2024-09-27
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors XL495, ADC cytotoxic agents - Solid Cancers, Solid Tumor Cancer	Phase 1	Terminated	Exelixis	9	2024-10-17	2025-06-25
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Intraperitoneal infusion of FAST CEA-targeted CAR-T, CEA CAR-T cells - Colorectal Cancer, Solid Cancers	Phase 1	Completed	Weijia Fang, MD	58	2022-05-25	2026-07-15
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Atezolizumab, Emactuzumab - Solid Cancers	Phase 1	Completed	Hoffmann-La Roche	221	2015-01-19	2020-08-27
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors Atezolizumab, Bevacizumab, Interferon alfa-2b - Solid Cancers	Phase 1	Completed	Hoffmann-La Roche	158	2014-08-18	2020-05-12
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Grape Seed Extract, Vitamin D - Solid Cancers	Phase 1	Completed	Medical University of South Carolina	22	2013-03-01	2018-05-18
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors GDC-0980, bevacizumab, carboplatin - Solid Cancers	Phase 1	Completed	Genentech, Inc.	75	2011-09-01	2016-11-02
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors GDC-0980, bevacizumab, capecitabine - Solid Cancers	Phase 1	Completed	Genentech, Inc.	41	2011-07-01	2016-11-02
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer Fulvestrant, GDC-0032, Letrozole - Solid Cancers, Non-Hodgkin's Lymphoma	Phase 1	Terminated	Genentech, Inc.	674	2011-03-16	2024-07-31
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol - Solid Cancers	Phase 1	Completed	Genentech, Inc.	52	2010-11-01	2015-06-29
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma GDC-0917 - Solid Cancers	Phase 1	Completed	Genentech, Inc.	42	2010-10-01	2016-11-02
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors MINT1526A, bevacizumab - Solid Cancers	Phase 1	Completed	Genentech, Inc.	54	2010-06-01	2016-11-02
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors GDC-0623 - Solid Cancers	Phase 1	Completed	Genentech, Inc.	61	2010-04-01	2016-11-02
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors GDC-0068 - Solid Cancers	Phase 1	Completed	Genentech, Inc.	52	2010-03-01	2016-07-04
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors MEGF0444A, bevacizumab, paclitaxel - Solid Cancers	Phase 1	Completed	Genentech, Inc.	64	2010-02-01	2016-11-02

Showing 20 of 29. Sign in to see all of them.

Narrower conditions

Neoplasms (3)  ·  Stomach Neoplasms (3)  ·  Carcinoma, Renal Cell (2)  ·  Colorectal Neoplasms (2)  ·  Endometrial Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Ataxia Telangiectasia (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)

Broader conditions

Neoplasms (6)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms by Site (5)  ·  Digestive System Diseases (4)  ·  Digestive System Neoplasms (4)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Urogenital Diseases (4)  ·  Urogenital Neoplasms (4)  ·  Carcinoma (3)  ·  Gastrointestinal Diseases (3)  ·  Gastrointestinal Neoplasms (3)  ·  Male Urogenital Diseases (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Stomach Diseases (3)

Interventions

Bevacizumab (7)  ·  Paclitaxel (3)  ·  1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (2)  ·  Carboplatin (2)  ·  HhAntag691 (2)  ·  atezolizumab (2)  ·  parsatuzumab (2)  ·  vesencumab (2)  ·  2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine (1)  ·  2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1)  ·  Capecitabine (1)  ·  Cisplatin (1)  ·  Docetaxel (1)  ·  Fulvestrant (1)  ·  GDC-0152 (1)

Sponsors

Genentech, Inc. (17)  ·  Hoffmann-La Roche (2)  ·  Beijing Tide Pharmaceutical Co., Ltd (1)  ·  Biotech Pharmaceutical Co., Ltd. (1)  ·  Danatlas Pharmaceuticals Co., Ltd (1)  ·  Ellipses Pharma (1)  ·  Exelixis (1)  ·  LaunXP Biomedical Co., Ltd. (1)  ·  Medical University of South Carolina (1)  ·  Semafore Pharmaceuticals (1)  ·  Shanghai Cell Therapy Group Co.,Ltd (1)  ·  Weijia Fang, MD (1)

Countries

United States (15)  ·  China (5)  ·  Spain (5)  ·  France (2)  ·  Belgium (1)  ·  Canada (1)  ·  Netherlands (1)  ·  Taiwan (1)

Top investigators

Rainer Brachmann, M.D. (2)  ·  Chia Portera, M.D., Ph.D. (1)  ·  Dawn Colburn, Pharm.D. (1)  ·  Donald L Durden, MD, PhD (1)  ·  Harald Weber, M.D. (1)  ·  Ina Rhee, M.D. (1)  ·  Iris Chan, M.D., Ph.D. (1)  ·  Jennifer Low, M.D. (1)  ·  Jerry Hsu, M.D. (1)  ·  Louie Naumovski, M.D., Ph.D. (1)  ·  Premal Patel, M.D. (1)  ·  Premal Patel, M.D., Ph.D. (1)  ·  Weijia Fang, M.D (1)

Results publications

PMID 22623056, PMID 22921184, PMID 25009010, PMID 27872130, PMID 28250200, PMID 34471960, PMID 35577503, PMID 38937298, PMID 39734708, PMID 41760800

NIH funding

2014 (2), 2009 (1)